Krystal Biotech, Inc. (KRYS) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Pittsburgh, PA, 미국. 현재 CEO는 Krish S. Krishnan.
KRYS 을(를) 보유 IPO 날짜 2017-09-20, 275 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $7.89B.
Krystal Biotech, Inc. is a clinical-stage biotechnology company developing redosable gene therapy treatments for serious rare diseases. The company's lead product candidate, beremagene geperpavec (B-VEC), is in Phase III clinical trials for dystrophic epidermolysis bullosa, with additional pipeline programs targeting congenital ichthyosis, aged skin conditions, cystic fibrosis, and Netherton syndrome at various development stages. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech focuses on addressing unmet medical needs in dermatological and genetic disorders through innovative gene therapy approaches.
